# Angiotensin Receptor Neprilysin Inhibitor

#### Introduction

- Angiotensin receptor neprilysin inhibitor is a new class of medicine using in patient with HFrEF.
- Valsartan/sacubitril (LCZ 696 or Entresto®) is the first and currently only medication in this class.


## Mechanism of action


- Val/Sac has 2 main mechanisms
  - 1. Valsartan an angiotensin 1 receptor blocker
  - 2. Sacbritil a neprilysin inhibitor
    - Neprilysin (aka neutral endopeptidase NEP) is an enzyme that degrades many peptides including natriuretic peptides (NP)
    - Inhibiting neprilysin results in elevated ANP, BNP and many peptide
- Overall effect is vasodilatation,  $\downarrow$  RAAS activation  $\downarrow$  Na retention (clinical significant?)

# PARADISE-HF study (NEJM 2014)

<ul> <li>Design:</li> </ul>	Multicenter, randomized, double-blind,					
	active-controlled, event-driven trial.		nimum required			
<ul> <li>Study Pop:</li> </ul>	Adult, stable HFrEF, EF < 35%, NYHA II-IV, inhibitors and angiotensin converting enz					
	elevated NP level, tolerate enalapril 10	ACE	- Minimum daily	ARBs	Minimum	
	mg/d (or equivalence of ACEI/ARB)	inhibitors	dose		dose	
• N	8442 patients	Enalapril	10 mg	Candesartan	16 mg	
- 11	•	Captopril	100 mg	Eprosartan	400 mg	
	(63 yo, 80% male, EF 29%, 70% NYHA II,	Cilazapril Fosinopril	2.5 mg 20 mg	Irbesartan Losartan	150 mg 50 mg	
	60% ischemic)	Lisinopril	10 mg	Olmesartan	10 mg	
<ul> <li>Intervention:</li> </ul>	2 run-in periods prior to randomize, then	Moexipril	7.5 mg	Telmisartan	40 mg	
• Intervention.		Perindopril	4 mg	Valsartan	160 mg	
	- Valsartan/sacubitril 200 mg bid or	Quinapril	20 mg			
	- Enalapril 20 mg bid	Ramipril	5 mg			
	- 0	Trandolapril	2 mg			
<ul> <li>Background rx:</li> </ul>	93% BB, 54% MRA	Zofenopril	30 mg			
• Follow up:	mean of 27 months					
• Result:	Significantly reduced composite endpoint of	CV death o	or HF-reho	spitaliza	ation	
(figure)	Significantly reduced composite endpoint of					
(IIV)	Significantiv reduced composite endpoint of	uv dealn				

- Significantly reduced composite endpoint of CV death (figure) Significantly reduced composite endpoint of HF-rehospitalization
- Adverse effect Symptomatic hypotension (14%), Cr > 3 (1.5%), K > 6 (4%)





- Val/Sac is associated with more hypotension, but less AKI or hyperkalemia compared to enalapril
- Maybe more benefit in NYHA II compared to NYHA III-IV (p for interaction = 0.03)
- The same efficacy regardless of with or without MRA.
- The same efficacy regardless of starting BP, EF, or age group within PARADIGM-HF study.
- Improve quality of life by MCCQ.

#### Concerns and unknown

- Run-in period design may exaggerate reported benefits when compare to real world practice.
- Run-in period design may underestimate reported S/E compare to real world practice.
- There is only 1 RCT of Val/Sac i.e. PARADIGM-HF, but a very low p value. It is unlikely to have a 2<sup>nd</sup> trial in HFrEF.
- In patient with HFrEF, unknown benefits/adverse effect in
  - ACEI/ARB naïve patient
  - "Adding MRA" or "switching ACEI/ARB to ARNI" first is better.
  - NYHA I

dy daily doses of

onverting enzyme blockers

Minimum dail

- Unstable AHF e.g. recent admission
- Unknown benefit in HFpEF
- ARNI also increase many other peptides which may result in adverse effect (angiotensin, endothelin, bradykinin, Beta-amyloid).
- Unknown effect on LV remodeling e.g. LVEF, LEVEDD.
- Cost effective? ICER = \$45,000 (JAMA Cardiol. 2016;1(6):666-672.)

#### Guideline Statement

Society	Statement	COR	LOE		
ACC/AHA 2017	In patients with chronic symptomatic HFrEF NYHA class II or III who tolerate an ACE inhibitor or ARB, replacement by an ARNI is recommended to further reduce morbidity and mortality	I	B-R		
ESC 2016	Sacubitril/valsartan is recommended as a replacement for an ACE-I to further reduce the risk of HF hospitalization and death in ambulatory patients with HFrEF who remain symptomatic despite optimal treatment with an ACE-I, a beta-blocker and an MRA	I	В		

# Using ARNI

- Use in patient with adequate BP (SBP > 100), GFR > 30 and K < 5.2.
- Replacing ACEI/ARB (not adding).
- Starting dose at 100 mg bid, in patient who use to tolerate ACEI/ARB.
- Consider lower starting dose (25-50 mg bid) if ACEI/ARB naïve or was on low dose of ACEI/ARB.
- "36-hour wash out period" when switching from ACEI to ARNI
- Up titrate g 2 weeks to 200 mg bid.
- S/E include othostatic symptoms, hypotension,  $\triangle$ Cr or  $\triangle$ K, If having S/E consider  $\checkmark$  diuretics,  $\downarrow$  other BP meds,  $\downarrow$ K supplement, or  $\downarrow$ ARNI.
- BNP level in patient who is on ARNI is unreliable, use NT-proBNP level.
- Contraindicate in pregnancy or try to be pregnant.

### Recommend reading

 McMurray JJV, et al. "Angiotensin-neprilysin inhibition versus enalapril in heart failure". NEJM 2014. 371(11):993-1004.